Bioventus (BVS)
NASDAQ:BVS
Total Valuation
Bioventus has a market cap or net worth of $748.39M. The enterprise value is $876.53M.
Market Cap$748.39M
Enterprise Value$876.53M
Share Statistics
Bioventus has 67,368,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding67,368,050
Owned by Insiders31.78%
Owned by Institutions46.35%
Financial Efficiency
Bioventus’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 10.79%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)10.79%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee610.85K
Profits Per Employee0.00
Employee Count930
Asset Turnover0.83
Inventory Turnover2.26
Valuation Ratios
The current PE Ratio of Bioventus is 21.8. Bioventus’s PEG ratio is -0.13.
PE Ratio21.8
PS Ratio0.87
PB Ratio2.69
Price to Fair Value2.69
Price to FCF6.94
Price to Operating Cash Flow8.16
PEG Ratio-0.13
Income Statement
In the last 12 months, Bioventus had revenue of 568.09M and earned 22.73M in profits. Earnings per share was 0.34.
Revenue568.09M
Gross Profit382.43M
Operating Income58.55M
Pretax Income25.71M
Net Income22.73M
EBITDA105.56M
Earnings Per Share (EPS)0.34
Cash Flow
In the last 12 months, operating cash flow was 74.67M and capital expenditures -2.56M, giving a free cash flow of 72.11M billion.
Operating Cash Flow74.67M
Free Cash Flow72.11M
Free Cash Flow per Share1.07
Dividends & Yields
Bioventus pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change-2.97%
50-Day Moving Average8.40
200-Day Moving Average7.38
Relative Strength Index (RSI)59.33
Average Volume (3m)257.41K
Important Dates
Bioventus upcoming earnings date is May 12, 2026, After Close (Confirmed).
Last Earnings DateMar 5, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Bioventus as a current ratio of 1.70, with Debt / Equity ratio of 169.11%
Current Ratio1.70
Quick Ratio1.19
Debt to Market Cap0.60
Net Debt to EBITDA2.46
Interest Coverage Ratio2.21
Taxes
In the past 12 months, Bioventus has paid -1.56M in taxes.
Income Tax-1.56M
Effective Tax Rate-0.06
Enterprise Valuation
Bioventus EV to EBITDA ratio is 7.16, with an EV/FCF ratio of 10.58.
EV to Sales1.33
EV to EBITDA7.16
EV to Free Cash Flow10.58
EV to Operating Cash Flow10.22
Balance Sheet
Bioventus has $51.24M in cash and marketable securities with $311.35M in debt, giving a net cash position of -$260.11M billion.
Cash & Marketable Securities$51.24M
Total Debt$311.35M
Net Cash-$260.11M
Net Cash Per Share-$3.86
Tangible Book Value Per Share-$2.21
Margins
Gross margin is 67.32%, with operating margin of 10.31%, and net profit margin of 4.00%.
Gross Margin67.32%
Operating Margin10.31%
Pretax Margin4.53%
Net Profit Margin4.00%
EBITDA Margin18.58%
EBIT Margin10.31%
Analyst Forecast
The average price target for Bioventus is $15.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$15.00
Price Target Upside63.93% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast1.58%
EPS Growth Forecast―